Compare Eli Lilly And Co (LLY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MINISO Group Holding Ltd — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while MINISO Group Holding Ltd trades at $9.65 (market cap $2.65B). The key difference: Eli Lilly And Co is far larger — about 392.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.34%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and MINISO Group Holding Ltd for 25 Days on average.
| LLY | MNSO | |
|---|---|---|
Market Cap | $1.04T | $2.65B |
Volume | 3,064,878 | 747,763 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $22.75 |
52-Week Low | $799.57 | $8.60 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $1.09T | $3.52B |
Dividend Yield | 0.59% | 7.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
